Dramatic improvement after tocilizumab of severe COVID ‐19 in a child with sickle cell disease and acute chest syndrome
De Luna et al, recently reported a favorable outcome of an acute chest syndrome (ACS) related to a SARS-Cov-2 infection treated with tocilizumab (TCZ), in a 45-year-old male patient with homozygous sickle cell disease (SCD). Following this successful observation, TCZ was administered to a teenage girl with SCD who developed a severe
COVID-19 associating ACS and pulmonary embolism.
Read the full case report here.